Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 1.00 |
| ▸ | FYN | P06241 | 12/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3031885 | 0.93 | MKNK1 (1.00) | MKNK1FYNKCNH2 | |
| SCHEMBL3042012 | 0.92 | MKNK1 (0.85) | MKNK1FYNKCNH2 | |
| SCHEMBL3036473 | 0.88 | MKNK1 (0.81) | MKNK1FYNKCNH2 | |
| SCHEMBL3036704 | 0.87 | MKNK1 (0.77) | MKNK1FYNKCNH2 | |
| SCHEMBL3043819 | 0.87 | MKNK1 (0.77) | MKNK1FYNKCNH2 | |
| SCHEMBL3043433 | 0.85 | MKNK1 (0.80) | MKNK1FYNKCNH2 | |
| SCHEMBL3033275 | 0.85 | MKNK1 (0.76) | MKNK1FYNKCNH2 | |
| SCHEMBL3038068 | 0.84 | FYN (0.72) | MKNK1FYN | |
| SCHEMBL3045303 | 0.82 | MKNK1 (0.71) | MKNK1FYNKCNH2 | |
| SCHEMBL3027253 | 0.82 | MKNK1 (0.68) | MKNK1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | claimed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| EP-2920176-B1 | AMINOIMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2920176-B1 | AMINOIMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| EP-2714692-B1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20150038485-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-05 | — | — | US | disclosed |
| US-20150038485-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-05 | — | — | US | disclosed |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| WO-2014076162-A1 | AMINOIMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-22 | — | — | WO | disclosed |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038485-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | CCND2, CCND1, CCNI | MKNK1 3025/4885FYN 1953/4885KCNH2 3233/4885 |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | CCND2, CCND1, VEGFA | MKNK1 3763/4885FYN 2261/4885KCNH2 2154/4885 |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | MKNK1, MKNK2, MAP4K5 | MKNK1 1/4885FYN 884/4885KCNH2 1190/4885 |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | MKNK1 816/4885FYN 3/4885KCNH2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.